NCT07101471Completed
Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
A Prospective and Observational Study for Safety and Effectiveness Evaluation of Rhofanib® (Tofacitinib) in Patients With Alopecia.
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- No phase declared
- Sponsor
- NanoAlvand
- Participants (registry)
- 296
- Start
- August 2020
- Primary completion
- June 2025
- Study completion
- June 2025
- Last registry update
- August 2025
- Countries
- Iran
Conditions studied: Alopecia Totalis/Universalis, Alopecia Areata(AA)
Interventions: Tofacitinib
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.